XML 45 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and contingencies - AbbVie Collaboration Agreement - (Details)
$ in Millions
1 Months Ended 3 Months Ended
Feb. 28, 2018
USD ($)
item
Feb. 28, 2015
USD ($)
Mar. 31, 2018
USD ($)
item
Genzyme      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Non-refundable upfront payment received   $ 65.0  
Collaborative Arrangement | AbbVie      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Research compounds number | item 3    
Non-refundable upfront payment received $ 69.0    
First Research Compound payment 80.0    
Two additional research compounds payment to be received for each $ 30.0    
Number of additional research compounds | item 2    
One-time payment upon exercise of license option $ 75.0    
Milestone payments to be received for licensed compound in case Alzheimer disease indication 550.0    
Milestone payments to be received for licensed compound in case first indication other than Alzheimer disease 230.0    
Milestone payments to be received for licensed compound for subsequent non-Alzheimer disease indication $ 115.0    
Number of development options | item 1   3
Number of antibodies encoded by virus | item 1    
Deferred revenue     $ 68.6
Revenue recognized     0.4
Allocation of Transaction Price      
Allocation of Transaction Price     69,000.0
Collaborative Arrangement | AbbVie | Minimum      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Number of research antibodies | item 2    
The number of Licensed Products | item 1    
Collaborative Arrangement | AbbVie | Maximum      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Antibodies to include in Research Period | item 5    
Number of research antibodies | item 3    
Collaborative Arrangement | AbbVie | Research Services      
Allocation of Transaction Price      
Allocation of Transaction Price     34,482.0
Collaborative Arrangement | AbbVie | First Development Option Material Right      
Allocation of Transaction Price      
Allocation of Transaction Price     34,518.0
Collaborative Arrangement | Genzyme      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Non-refundable upfront payment received   $ 65.0  
Deferred revenue     51.2
Revenue recognized     $ 0.5